Fibrinolytic Vessel Wall Activator in Arterial Thrombosis

  • H. Stormorken
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 164)


The general consensus is that the fibrinolytic system is the main defence system against thrombo-embolism on the venous side, as illustrated in Fig. 1. This is reasonable because the venous thrombus is more or less a coagulation thrombus where fibrin is predominant, whereas on the arterial side the platelets are the dominant constituent. However, in a fully developed arterial thrombus there is after all some fibrin, the breakdown of which could lead to instabilization and thus halting further growth. It is even possible that the fibrinolytic system might be of importance in the early phase of thrombus formation, since forming fibrin may induce the platelet release reaction. As the fibrin in this stage is most susceptible to plasmin, and the vessel wall activator is stored very close to the initial events, it is feasible that an attack on the fibrin during formation would be of particular importance as a defence phenomenon. However, there has been very little attempt to devise models to pursue this possibility. So far, the evidence for a role of the fibrinolytic system in the defence against arterial thrombosis stems from observations on different patient-groups, and this evidence is steadily becoming stronger.


Factor VIII Fibrinolytic Activity Arterial Thrombosis Fibrinolytic System Abstract Book 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Almér, L.O., Pandolfi, M. and Åberg, M., 1975, The plasminogen activator activity of arteries and veins in diabetes mellitus. Thromb. Res. 6:177–182.PubMedCrossRefGoogle Scholar
  2. Andersen, P., Arnesen, H. & Hjermann, I., Hyperlipoproteinemia and reduced fibrinolytic activity in healthy coronary risk men. In: Abstract book, Vth Int. Conf. Synthet. fibrinolytic agents, Malmö 1980, p. 104.Google Scholar
  3. Arnesen, H., Nordby, E., Andersen, P. & Godai, H.C., A comparison between the euglobulin clot lysis time and the fibrin plate method for the estimation of fibrinolytic activity after venous stasis. Abstract book, Vth Int. Conf. Synthet. fibrinolytic agents, Malmö 1980, p. 124.Google Scholar
  4. Kluft, C., Blood fibrinolysis. Thesis. Dutch Efficiency Bureau. Pijnacher 1978.Google Scholar
  5. Mettinger, K.L., Nyman, D., Kjellin, K.G., Sidén, Å. & Søderstrøm, C.E., 1979, Factor VIII related antigen, antithrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebral disease. J. Neurol. Sci. 41:31–38.PubMedCrossRefGoogle Scholar
  6. Mettinger, K.L. et al.: (in press)Google Scholar
  7. Nilsson, I.M., Åberg, M., Holmberg, L. & Vilhart, H., The release mechanism of plasminogen activator and F. VIII as studied by injection of DDAVP and venous occlusion. Abstract book, Vth Int. Conf. Synthet. fibrinolytic agents, Malmö 1980, p. 59.Google Scholar
  8. Nilsson, I.M., Fibrinolysis in diabetes and obesity. Advances in coagulation, fibrinolysis, platelet aggregation and atherosclerosis. Proc. Europ. Symp., ed. Strano, A., C.E.P.I., Roma 1978, p. 95–105.Google Scholar
  9. Stormorken, H. & Erikssen, J., 1979, Plasma antithrombin III and factor VIII antigen in relation to angiographic findings, angina and blood groups in middle aged men. Thrombos. Haemostas. 38:874–880.Google Scholar
  10. Wahlberg, T.B., Blombäck, M. & Övermark, I., 1980, Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease. Acta. Med. Scand. 27:385–390.Google Scholar
  11. Walker, I.D., Davidson, J.F., Hutton, I. & Lawrie, T.D.V., 1977, Disordered “fibrinolytic potential” in coronary heart disease. Thromb. Res. 10:509–520.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • H. Stormorken
    • 1
  1. 1.Research Institute for Internal MedicineRikshospitaletOslo 1Norway

Personalised recommendations